ANGLE plc company

ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. ANGLE also owns a successful specialist technology consultancy and a major investment in a business with a unique computer graphics technology platform. ANGLE was founded by Andrew Newland in 1994 to bridge a gap between research and the market. ANGLE's business model is to set up, own and operate technology companies to commercialise world-class research. The business has matured so that it now focuses on its established 90%+ owned businesses with unique high value patent protected medical technologies addressing multi-billion dollar markets. ANGLE's lead product is the Parsortix cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE has launched a product for the research market and is aiming to secure CE Mark regulatory approval for the clinical market in 2013 with FDA approval in 2014.
Technology: Regenerative Medicine
Industry: Personalized Medicine
Headquarters: Guildford, Surrey, United Kingdom
Founded Date: 1994
Employees Number: 51-100
Funding Status: IPO
Total Funding: $250K
Estimated Revenue: Less than $1M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership